Though the decreases in viral antigens partially results from the cell growth restraint, EGFR inhibitors are still clinically promising since the grow restraint of infected hepatocytes is favorable for the cure of HBV infection as well as the elimination of HCC risk. Here, EGFR is linked to hepatocellular carcinoma.